ClinicalTrials.gg
CompletedNCT05332210Updated Apr 28, 2026

Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis

A Phase 3 interventional study of HBM9161 Injection (680mg) in Myasthenia Gravis, sponsored by Harbour BioMed (Guangzhou) Co. Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-28.

Sponsored by Harbour BioMed (Guangzhou) Co. Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
111
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 88 studies in Myasthenia Gravis with a site in China — 48 open to participants now, 60 under way, 17 of them phase 3. Myasthenia Gravis · China.

Enrollment
19th of 67
111 · median 40
Started
2022
with 4 others
Phase 3
24 of 88
7 open now
Registered
29th of 88
by date
Lead sponsor
3 of 88
Harbour BioMed (Guangzhou) Co. Ltd.

Among the 88 studies in Myasthenia Gravis with a site in China, this one is the 19th largest by enrollment of the 67 interventional ones that give a count, is one of 5 that started in 2022, is one of 24 in phase 3, and was the 29th registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

48 of the 88 studies in Myasthenia Gravis with a site in China are open now. Recruiting first, the newest first:

43 more — sign in →

All 48 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Myasthenia Gravis with a site in China, or all of them as a file.
02

Study summary

The primary study objective is to evaluate medium- and long-term safety of HBM9161 in combination with background treatment for gMG patients through the observation on adverse events and laboratory abnormalities during study period.

03

Conditions studied

  • Myasthenia Gravis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Completed the HBM9161.3 Phase 3 study
  2. Signed written .
  3. Suitable for continued treatment with HBM9161 as judged by the investigator.
  4. Female patients of and male patients with female partners of childbearing potential can participate in this study, but reliable measures must be taken (such as physical barrier contraception (patients and their partners), contraceptive pills or patches, spermicide and barrier or intrauterine device). Up to 60 days after the last dose.
  5. A negative urine pregnancy at baseline must be observed for women of childbearing age.

Exclusion criteria

Exclusion Criteria:

  1. Had received any other clinical study drug since the administration of the study drug in the 9161.3 Phase 3 study.
  2. Females who are pregnant or lactating or planning to become pregnant during the study period, or females of who are not using an effective method of .
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
111 participants (actual)

Study arms

  • Experimental
    HBM9161 Drug Product (680mg)

    HBM9161 680mg: subcutaneous injection, 6 times per treatment cycle, once a week; the second cycle of treatment may start 4 weeks after the last dose of the previous treatment cycle; if the disease state is still stable 4 weeks after the last dose, the observation can be continued until the disease activity is aggravated (improvement of MG-ADL \< 3 points compared with the previous treatment cycle), and the next treatment cycle can start. The dose may be reduced to 340 per investigator's discretion. Return to the dose of 680 mg is not permitted after a dose reduction is made.

    Drug: HBM9161 Injection (680mg)

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of AEs during the study

    Incidence of AEs

    Time frame: during the study,up to 24 weeks

Secondary outcomes

  1. Proportion of patients with sustained improvement

    Sustained reduction defined as MG-ADL score improved by ≥ 3 points from baseline for at least 4 consecutive weeks during the 9-week treatment cycle

    Time frame: during each treatment cycle (5-week treatment period + 4-week observation period, from the first dose of the cycle to Day 64 of the cycle)

  2. During the 24-week study, proportion of time that MG-ADL improved from baseline by 3 or more points

    Time frame: during the study,up to 24 weeks

  3. Proportion of time remained in Minimal Symptom Expression

    from baseline to Week 24, percentage of time MG-ADL score being 0 or 1

    Time frame: during the study,up to 24 weeks

  4. Improvement of patients' quality of life

    Improvement of patients' quality of life

    Time frame: during the study,up to 24 weeks

  5. Incidence and duration of serum anti-HBM9161 antibodies and neutralizing antibodies

    Incidence and duration of serum anti-HBM9161 antibodies and neutralizing antibodies

    Time frame: during the study,up to 24 weeks

07

Study locations

1 site
  • Huashan Hospital, Fudan University
    Shanghai, Shanghai Municipality, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Apr 2024, 21 months.

Of 43 industry-sponsored phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's 21 months is below that.

Counting every sponsor, half of 52 studies reached it within 30 months; a quarter within 20 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2022
First posted
Apr 18, 2022
StartActual
Jun 30, 2022
Primary completionActual
Apr 26, 2024
CompletionActual
Apr 26, 2024
Last update
Apr 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05332210
Lead sponsor
Harbour BioMed (Guangzhou) Co. Ltd.
Responsible party
Sponsor
First posted
Apr 18, 2022
Start date
Jun 30, 2022
Primary completion
Apr 26, 2024
Completion
Apr 26, 2024
Last update
Apr 28, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HBM9161

Start the discussion